Nextleaf Solutions Ltd. (” Nextleaf Solutions “, ” OILS “, or the ” Company “) ( CSE: OILS ) ( OTCQB: OILFF ), Canada’s most innovative cannabis extractor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“ Nextleaf Labs ”), a Health Canada licensed standard processor, has entered into a Cannabis Extraction Agreement (the “ Agreement ”) with Natural MedCo Ltd.(“ NMC ”), a wholly-owned subsidiary of Eve & Co Incorporated (“ E ve & Co ”) ( TSX-V: EVE ) ( OTCQ B : EEVVF ). NMC is based in Strathroy, Ontario and operates over one million square feet of licensed production and distribution through provincial adult-use channels and international markets.

Cannabis Extraction Agreement


Pursuant to the Agreement, NMC will provide cannabis biomass to be processed into distilled THC and CBD oils at Nextleaf’s closed-loop extraction plant in Metro Vancouver. The resulting bulk THC and CBD oils will be sold by Nextleaf Labs through its Commercial Partners Program and the wholesale market, with the net proceeds of such sales to be shared by Nextleaf Labs and NMC. The initial term of the Agreement will end on the earlier of (a) 12 months, and (b) the date upon which 5,000 kilograms of cannabis biomass has been processed, and automatically renews thereafter for successive one-year terms.

Nextleaf Solutions’ investment in IP and its existing fixed asset base provides a robust platform to scale, and a clear competitive advantage to supply low-cost cannabinoid distillate produced at the Company’s ultra-efficient cannabis oil refinery in British Columbia.

“We are excited for the opportunity to support the launch of Eve & Co’s female-focussed cannabis 2.0 product lines in Canada,” stated Nextleaf Solutions’ CFO, Charles Ackerman. “Given our partner’s European Union certificate of Good Manufacturing Practise Compliance, and their ability to distribute into Germany, we expect to have opportunities to supply global markets with bulk THC and CBD oils and differentiated products,” continued Ackerman.

“We are excited about the opportunity to work with Nextleaf, which is such a ground-breaking company, and the opportunities our partnership will bring,” said Melinda Rombouts, CEO and President of Eve & Co. “Alliance with this group adds another revenue stream, which aligns well with our 2.0 female-focussed product line and exports to the European Union.”

About Nextleaf®

OILS is Canada’s most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. OILS wholesales THC and CBD oils and provides extraction services through its wholly owned subsidiary Nextleaf Labs Ltd., a Health Canada licensed processor. The Company owns a portfolio of over 50 issued patents and over 50 pending patents for the extraction, purification, and delivery of cannabinoids.  The Company’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter , LinkedIn , Facebook , and Instagram .

www.nextleafsolutions.com

For more information please contact:
Jason McBride
604-283-2301 (ext. 219)
investors@nextleafsolutions.com

On behalf of the Board of Directors of OILS,

Paul Pedersen, CEO

About Eve & Co.

Eve & Co, through its wholly-owned subsidiary NMC, holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received its European Union certificate of Good Manufacturing Practice. NMC was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation licence from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 square foot greenhouse located in Strathroy, Ontario.

For further information, please contact:

Melinda Rombouts
President and Chief Executive Officer
Eve & Co Incorporated
Telephone: (855) 628-6337

Rory Taylor
Interim Chief Financial Officer
Eve & Co Incorporated
Telephone: (855) 628-6337

CAUTIONARY STATEMENT

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company and NMC’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company and Eve & Co’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A and Eve & Co’s MD&A, respectively, for the most recent fiscal period. The Company and Eve & Co’s management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company and Eve & Co, as applicable. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved this press release.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less